Business Wire

MN-SMITHS-MEDICAL

16.6.2021 20:02:10 CEST | Business Wire | Press release

Share
Smiths Medical Issues Worldwide Notification Regarding the Recall of Jelco® Hypodermic Needle-Pro® Fixed Needle Insulin Syringe With Skewed Graduation Markings

Smiths Medical has become aware of specific models and lots of Jelco® Hypodermic Needle-Pro® Fixed Needle Insulin Syringes that may exhibit skewed odd number line graduation markings on their syringe barrels. Markings skewed approximately 20 degrees upward have been identified.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210616005888/en/

Affected Models and Lot Numbers:

Model
Number

Name

Lot Number

4428-1

Jelco® Hypodermic Needle-Pro® Fixed Needle Insulin Syringe 28Gx1/2” 1CC

4046543 and 4062235

4429-1

Jelco® Hypodermic Needle-Pro® Fixed Needle Insulin Syringe 29Gx1/2” 1CC

4014096, 4031846, 4031845, 4040734, 4043536, 4046545, 4046546, 4062239, 4062240, 4062238 and 4062242

Please reference the attachment for an illustration of the skewed graduation marking on the syringe barrel.

As a result of this issue, there is potential for administration of an incorrect dose of insulin, which could result in hyperglycemia (which may lead to ketoacidosis) or hypoglycemia (which may lead to seizures). This may result in serious harm or death.

Smiths Medical has received no reports of death or serious injury related to this issue.

Smiths Medical is issuing Recall Notices and Response Forms to consignees of Affected Models and Lot Numbers to instruct them that they must quarantine and return the product.

Additional Information:

This action has been designated as a Class 1 recall by the U.S. Food and Drug Administration (FDA).

Home Healthcare Environments

The lot number can be found on the packaging for the syringe. Do not use any syringes with the affected lot numbers. The patient or caretaker should contact the pharmacy, home healthcare provider or medical facility that provided the syringe to arrange for return of the syringe and replacement.

Smith Medical Contact Information

Consumers with questions regarding this recall may contact Smiths Medical via telephone at 1-(800)-258-5361.

Consumers may also contact Smiths Medical online at https://smiths-medical.custhelp.com .

Specific questions on the recall should be directed to fieldactions@smiths-medical.com .

FDA MedWatch Reporting

Adverse reactions or quality problems experienced with the use of these products may also be reported to the FDA’s MedWatch Program by:

  • MedWatch website at www.fda.gov/medwatch
  • Phone: 1-800-FDA-1033
  • Fax: 1-800-FDA-0178
  • Mail: MedWatch, HF-2, FDA, 5600 Fishers Lane, Rockville, MD 20852

About Smiths Medical

A leading supplier of specialized medical devices and equipment for global markets, focusing on the medication delivery, vital care and safety devices market segments. For more information, visit www.smiths-medical.com .

About Smiths Group

A global technology company that has been operating for nearly 170 years, delivering products and services for the medical technology, security and defense, general industrial, energy and space and commercial aerospace markets worldwide. Smiths Group plc employs c. 23,000 colleagues in over 50 countries and is listed on the London Stock Exchange. For more information visit www.smiths.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SuperElastic* Material Unveiled by Angelalign2.11.2026 18:46:00 CET | Press release

New, Improved Clear Aligner Material Gives Orthodontists More Control Angelalign Technology Inc. (6699.HK) (“Angel”)http://www.angelaligner.com, a global clear aligner leader, today unveiled SuperElastic (MC-SE*), a new propietary aligner material that is a significant breakthrough in performance over its current material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261102654659/en/ Specialists in orthodontics have long asked for new aligner materials that enable better treatment for complex cases: biologically safe force levels, a large elastic working range, and strength and toughness. MC-SE* provides all of them. “Angel is commited to innovation and never settling for 'good enough'. MC-SE* is the result of seven years of materials research, testing and manufacturing optimization. The new material aims to create a new generation of aligner material that allows orthodonists to differentiate their treatment from other tre

Galderma Announces Proposed Board Appointments and Chief Financial Officer Transition2.11.2026 18:00:00 CET | Press release

The Company will hold an Extraordinary General Meeting on December 3, 2026 to further reinforce its Board of DirectorsAd hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced proposed changes to its Board of Directors, aimed at further strengthening its governance and supporting its long-term growth. The company also announced that Luigi La Corte, Chief Financial Officer (CFO), has decided to leave Galderma to pursue a significant new opportunity. Luigi La Corte will continue to fulfil his responsibilities as CFO during the transition period, supporting business continuity and a smooth handover. The company will communicate further details regarding succession arrangements and the transition timeline in due course. The Board of Directors is proposing the election of Rosalind Brewer and Petra Rumpf as new Board members. Both candidates bring extensive leadership and governance experience, alongside expertise span

Donaldson Introduces Alpha-Pore™ Technology Platform for Extended Sterile Filtration Performance2.11.2026 15:35:00 CET | Press release

Donaldson Company, Inc. (NYSE: DCI), a leading worldwide manufacturer of innovative filtration products and solutions, today announced Alpha‑Pore™ technology, a next generation sterile filtration platform engineered to extend filter service life while maintaining critical process performance. Built for critical applications, Alpha‑Pore technology enables longer filter run time compared with competitive single- and dual-layer polyethersulfone (PES) membrane filters, while maintaining flow characteristics, sterility assurance, and process integrity.* The platform is designed to help manufacturers improve operational efficiency through fewer changeouts and more consistent performance over time. Engineered for Extended Performance Sterile filtration processes often require balancing run time with key performance parameters such as flow, differential pressure, and contaminant retention. Alpha‑Pore technology is designed to achieve all three. By optimizing pore structure and filter architect

SBC Medical Forms Capital and Business Alliance with AtomicSoftware, Provider of the medicalforce Clinic Management Platform Used by 800+ Clinics in Japan2.11.2026 15:00:00 CET | Press release

Companies to co-develop AI features, starting with physician documentation support, to enhance medicalforce and SBC Medical’s in-house systems and drive per-clinic productivity and profitability SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“The Company” or “SBC Medical”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields, today announced that it entered into a capital and business alliance agreement on October 26, 2026, with AtomicSoftware Inc. (“AtomicSoftware”), the Tokyo-based provider of medicalforce, an all-in-one software-as-a-service (SaaS) platform for clinics. In connection with the alliance, SBC Medical has invested ¥600 million (approximately US$3.8 million) in AtomicSoftware’s Series C funding round. The two companies will co-develop AI features, beginning with a feature that supports physicians in preparing medical records. Key HighlightsProven platform: medicalforce is used by more than 800 clinics*1 in J

Smartly Launches Intelligence Pro to Connect Campaign Planning, Performance and Incrementality2.11.2026 15:00:00 CET | Press release

The new offering brings together planning, performance benchmarks, headroom analysis and incrementality signals to help marketers make more informed decisions across the campaign lifecycle Smartly, the AI-powered advertising technology company, today launched Intelligence Pro, a premium offering that brings together four capabilities to help marketers plan investment, understand true incrementality and determine where to spend their next dollar. Intelligence Pro connects causal inference models with planning tools to help marketers prove business impact and make faster decisions from increasingly complex data. “Marketing teams are inundated with data, but the challenge is identifying what signals are useful and turning them into a decision they can act on,” said Maxwell Tang, Chief Product Officer at Smartly. “Intelligence Pro brings forecasting, market context and state-of-the-art incrementality signals together to help marketers assess where to invest and what their media is contribu

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye